JP2022520402A5 - - Google Patents

Info

Publication number
JP2022520402A5
JP2022520402A5 JP2021547225A JP2021547225A JP2022520402A5 JP 2022520402 A5 JP2022520402 A5 JP 2022520402A5 JP 2021547225 A JP2021547225 A JP 2021547225A JP 2021547225 A JP2021547225 A JP 2021547225A JP 2022520402 A5 JP2022520402 A5 JP 2022520402A5
Authority
JP
Japan
Prior art keywords
cells
tgfβr2
cell
adora2a
cish
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018443 external-priority patent/WO2020168300A1/en
Publication of JP2022520402A publication Critical patent/JP2022520402A/ja
Publication of JP2022520402A5 publication Critical patent/JP2022520402A5/ja
Priority to JP2025015511A priority Critical patent/JP2025065213A/ja
Pending legal-status Critical Current

Links

JP2021547225A 2019-02-15 2020-02-14 免疫療法のための改変ナチュラルキラー(nk)細胞 Pending JP2022520402A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025015511A JP2025065213A (ja) 2019-02-15 2025-01-31 免疫療法のための改変ナチュラルキラー(nk)細胞

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962806457P 2019-02-15 2019-02-15
US62/806,457 2019-02-15
US201962841066P 2019-04-30 2019-04-30
US62/841,066 2019-04-30
US201962841684P 2019-05-01 2019-05-01
US62/841,684 2019-05-01
US201962943649P 2019-12-04 2019-12-04
US62/943,649 2019-12-04
PCT/US2020/018443 WO2020168300A1 (en) 2019-02-15 2020-02-14 Modified natural killer (nk) cells for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025015511A Division JP2025065213A (ja) 2019-02-15 2025-01-31 免疫療法のための改変ナチュラルキラー(nk)細胞

Publications (2)

Publication Number Publication Date
JP2022520402A JP2022520402A (ja) 2022-03-30
JP2022520402A5 true JP2022520402A5 (cg-RX-API-DMAC10.html) 2023-02-21

Family

ID=70009368

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547225A Pending JP2022520402A (ja) 2019-02-15 2020-02-14 免疫療法のための改変ナチュラルキラー(nk)細胞
JP2025015511A Pending JP2025065213A (ja) 2019-02-15 2025-01-31 免疫療法のための改変ナチュラルキラー(nk)細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025015511A Pending JP2025065213A (ja) 2019-02-15 2025-01-31 免疫療法のための改変ナチュラルキラー(nk)細胞

Country Status (15)

Country Link
US (1) US20220143084A1 (cg-RX-API-DMAC10.html)
EP (1) EP3924467A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022520402A (cg-RX-API-DMAC10.html)
KR (1) KR20210129105A (cg-RX-API-DMAC10.html)
CN (2) CN119979471A (cg-RX-API-DMAC10.html)
AU (1) AU2020221409B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021016046A2 (cg-RX-API-DMAC10.html)
CA (1) CA3128888A1 (cg-RX-API-DMAC10.html)
CL (2) CL2021002147A1 (cg-RX-API-DMAC10.html)
IL (1) IL285543A (cg-RX-API-DMAC10.html)
MX (1) MX2021009742A (cg-RX-API-DMAC10.html)
PE (1) PE20211959A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021552003A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202108644UA (cg-RX-API-DMAC10.html)
WO (1) WO2020168300A1 (cg-RX-API-DMAC10.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
CN114174325A (zh) * 2019-06-04 2022-03-11 恩卡尔塔公司 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
EP4061927A4 (en) * 2019-11-20 2024-11-13 Cartherics Pty. Ltd. METHOD FOR PROVIDING IMMUNE CELLS WITH ENHANCED FUNCTION
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
US20230383257A1 (en) * 2020-10-15 2023-11-30 Board Of Regents, The University Of Texas System Production of megakaryocytes and platelets in a co-culture system
CA3198905A1 (en) * 2020-10-19 2022-04-28 Caribou Biosciences, Inc. Dna-containing polynucleotides and guides for crispr type v systems, and methods of making and using the same
EP4232567A1 (en) * 2020-10-26 2023-08-30 Shoreline Biosciences, Inc. Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells
WO2022093868A1 (en) * 2020-10-26 2022-05-05 City Of Hope Engineered nk cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4255453A4 (en) * 2020-12-03 2025-03-26 Nkarta, Inc. Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4271798A1 (en) * 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CA3214473A1 (en) * 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
US20240254444A1 (en) * 2021-05-04 2024-08-01 Shoreline Biosciences, Inc. Engineered cells for therapy
WO2022242700A1 (en) * 2021-05-20 2022-11-24 Wuxi Biologics (Shanghai) Co., Ltd. Genetically modified nk cells and uses thereof
WO2022242701A1 (en) * 2021-05-20 2022-11-24 Wuxi Biologics (Shanghai) Co., Ltd. Genetically modified gamma-delta t cells and uses thereof
WO2022269393A1 (en) * 2021-06-23 2022-12-29 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
WO2022272292A2 (en) * 2021-06-23 2022-12-29 Editas Medicine, Inc. Engineered cells for therapy
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
CN119452085A (zh) * 2021-08-27 2025-02-14 宏基因组学公司 具有ruvc结构域的酶
CA3233160A1 (en) * 2021-09-29 2023-04-06 Alicja J. Copik Engineered nk cells and uses thereof
AU2022361488A1 (en) * 2021-10-05 2024-05-02 Cytovia Therapeutics, Llc Natural killer cells and methods of use thereof
CA3242360A1 (en) * 2021-12-10 2023-06-15 Beam Therapeutics Inc. Modified immune cells and methods of using the same
WO2024004814A1 (en) * 2022-06-27 2024-01-04 Kyoto University A METHOD FOR PRODUCING iPS CELL -DERIVED NATURAL KILLER CELLS
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
EP4353741A1 (en) * 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
WO2024102860A1 (en) * 2022-11-09 2024-05-16 Shoreline Biosciences, Inc. Engineered cells for therapy
CN115820645B (zh) * 2022-11-28 2023-09-22 上海恩凯细胞技术有限公司 制备沉默nkg2a基因的nk细胞的方法及其用途
WO2024197552A1 (en) * 2023-03-28 2024-10-03 Nuwacell Biotechnologies Co., Ltd. Genetically-modified pluripotent stem cells and derived natural killer cells and methods for producing the same
JP2026518850A (ja) * 2023-04-27 2026-06-10 武田薬品工業株式会社 Cd56+/cd3-細胞の増殖方法
CN116590237B (zh) * 2023-05-29 2023-10-31 上海贝斯昂科生物科技有限公司 一种遗传修饰的自然杀伤细胞及其制备和用途
CN116445416B (zh) * 2023-06-08 2023-10-17 山东兴瑞生物科技有限公司 一种基因修饰的car-nk细胞及其制备方法和应用
WO2025061158A1 (zh) * 2023-09-20 2025-03-27 士泽生物医药(苏州)有限公司 一种表达mcl1的低免疫原性细胞及其制备方法
WO2025213127A1 (en) 2024-04-05 2025-10-09 Indapta Therapeutics, Inc. Treatment of autoimmune diseases or conditions with natural killer cells
WO2025245399A1 (en) 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP5652783B2 (ja) * 2008-09-08 2015-01-14 独立行政法人理化学研究所 NKT細胞由来iPS細胞およびそれ由来のNKT細胞
WO2010108126A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
US20130011376A1 (en) 2009-12-29 2013-01-10 Gamida Cell Ltd. Methods for Enhancing Natural Killer Cell Proliferation and Activity
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
CN111218447B (zh) 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US9938521B2 (en) 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
SG11201608701QA (en) 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
JP7033453B2 (ja) * 2015-06-30 2022-03-10 セレクティス 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法
EP3828266B1 (en) * 2015-07-29 2022-11-23 ONK Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
EP4339287A3 (en) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
US12642852B1 (en) * 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
AU2016374497B2 (en) * 2015-12-16 2022-03-10 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
AU2017210031C1 (en) * 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
MX2018010484A (es) 2016-03-04 2019-01-10 Editas Medicine Inc Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
AU2017341736B2 (en) * 2016-10-12 2022-09-08 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
WO2018126074A1 (en) * 2016-12-30 2018-07-05 Celularity, Inc. Genetically modified natural killer cells
JP2020517259A (ja) * 2017-04-19 2020-06-18 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
US12359223B2 (en) 2018-01-30 2025-07-15 Editas Medicine, Inc. Systems and methods for modulating chromosomal rearrangements
CA3100045A1 (en) * 2018-05-11 2019-11-14 The Regents Of The University Of California Modification of immune cells to increase activity
AU2019386140B2 (en) * 2018-11-28 2026-05-28 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment

Similar Documents

Publication Publication Date Title
JP7267601B2 (ja) 多能性幹細胞を用いた免疫機能再建法
US12024717B2 (en) Method for reconstructing immune function using pluripotent stem cells
JP2025065213A (ja) 免疫療法のための改変ナチュラルキラー(nk)細胞
Barrett et al. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy
JP2021530999A (ja) 免疫改変多能性幹細胞由来のキメラ抗原受容体t細胞
JP2021530999A5 (cg-RX-API-DMAC10.html)
Zhu et al. Concise review: human pluripotent stem cells to produce cell-based cancer immunotherapy
Lamb Jr et al. γδ T cells: a new frontier for immunotherapy?
JP2021505131A (ja) 増強されたiPSC由来のエフェクター細胞を用いた免疫療法
JP2023501381A (ja) Stem細胞からのキメラ抗原受容体修飾t細胞の作製とその治療的使用
US20220226379A1 (en) Dnmt3a knock-out stat5 activated genetically engineered t-cells
JP2025507864A5 (cg-RX-API-DMAC10.html)
Gress et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of Relapse after Transplantation
Reuter et al. Immunostimulation by OX40 ligand transgenic Ewing sarcoma cells
Vanhee et al. Pluripotent stem cell based gene therapy for hematological diseases
Rein et al. Applications of gene editing technologies to cellular therapies
US20250368955A1 (en) B cell lineages derived from pluripotent cells
CN120265300A (zh) 来源于多能细胞的自然杀伤细胞谱系
Smerchansky et al. Engineered multicellular niches for pluripotent stem cell–derived immunotherapy
CN118647709A (zh) 效应细胞及其用于实体瘤中同种异体过继性细胞疗法的用途
JP2024506067A5 (cg-RX-API-DMAC10.html)
CN119220607B (zh) 编辑tim3基因获得功能强化的car-nk细胞的方法与应用
Coffey et al. Advances in pluripotent stem cell-derived natural killer cells for cancer immunotherapy
Bosslet et al. Clonal tumor cell variants arising by adaptation
Toishigawa et al. Platinum TALEN-mediated nonviral gene editing facilitates clinical-scale production of cancer antigen-reactive T cells